Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chronic Obstructive Pulmonary Disease (COPD)-Pipeline Review, H1 2015

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chronic Obstructive Pulmonary Disease (COPD)-Pipeline Review, H1 2015', provides an overview of the Chronic Obstructive Pulmonary Disease (COPD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chronic Obstructive Pulmonary Disease (COPD) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 8

Chronic Obstructive Pulmonary Disease (COPD) Overview 9

Therapeutics Development 10

Chronic Obstructive Pulmonary Disease (COPD)-Therapeutics under Development by Companies 12

Chronic Obstructive Pulmonary Disease (COPD)-Therapeutics under Investigation by Universities/Institutes 21

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline Products Glance 23

Chronic Obstructive Pulmonary Disease (COPD)-Products under Development by Companies 27

Chronic Obstructive Pulmonary Disease (COPD)-Products under Investigation by Universities/Institutes 41

Chronic Obstructive Pulmonary Disease (COPD)-Companies Involved in Therapeutics Development 42

Chronic Obstructive Pulmonary Disease (COPD)-Therapeutics Assessment 144

Drug Profiles 161

Chronic Obstructive Pulmonary Disease (COPD)-Recent Pipeline Updates 424

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects 503

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products 519

Chronic Obstructive Pulmonary Disease (COPD)-Product Development Milestones 526

Appendix 534

List of Tables

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2015 31

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD)-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 34

Number of Products under Development by Companies, H1 2015 (Contd..1) 35

Number of Products under Development by Companies, H1 2015 (Contd..2) 36

Number of Products under Development by Companies, H1 2015 (Contd..3) 37

Number of Products under Development by Companies, H1 2015 (Contd..4) 38

Number of Products under Development by Companies, H1 2015 (Contd..5) 39

Number of Products under Development by Companies, H1 2015 (Contd..6) 40

Number of Products under Development by Companies, H1 2015 (Contd..7) 41

Number of Products under Investigation by Universities/Institutes, H1 2015 43

Comparative Analysis by Late Stage Development, H1 2015 44

Comparative Analysis by Clinical Stage Development, H1 2015 45

Comparative Analysis by Early Stage Development, H1 2015 46

Comparative Analysis by Unknown Stage Development, H1 2015 47

Products under Development by Companies, H1 2015 48

Products under Development by Companies, H1 2015 (Contd..1) 49

Products under Development by Companies, H1 2015 (Contd..2) 50

Products under Development by Companies, H1 2015 (Contd..3) 51

Products under Development by Companies, H1 2015 (Contd..4) 52

Products under Development by Companies, H1 2015 (Contd..5) 53

Products under Development by Companies, H1 2015 (Contd..6) 54

Products under Development by Companies, H1 2015 (Contd..7) 55

Products under Development by Companies, H1 2015 (Contd..8) 56

Products under Development by Companies, H1 2015 (Contd..9) 57

Products under Development by Companies, H1 2015 (Contd..10) 58

Products under Development by Companies, H1 2015 (Contd..11) 59

Products under Development by Companies, H1 2015 (Contd..12) 60

Products under Development by Companies, H1 2015 (Contd..13) 61

Products under Investigation by Universities/Institutes, H1 2015 62

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 63

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 64

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Advinus Therapeutics Ltd., H1 2015 65

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Alba Therapeutics Corporation, H1 2015 66

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Alchemia Limited, H1 2015 67

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by AlgiPharma AS, H1 2015 68

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Amakem NV, H1 2015 69

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 70

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Apellis Pharmaceuticals, Inc., H1 2015 71

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 72

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Ario Pharma Ltd, H1 2015 73

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Asmacure Ltee, H1 2015 74

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Astellas Pharma Inc., H1 2015 75

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by AstraZeneca PLC, H1 2015 76

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Asubio Pharma Co., Ltd., H1 2015 78

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Axikin Pharmaceuticals, Inc., H1 2015 79

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Basilea Pharmaceutica AG, H1 2015 80

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Beech Tree Labs, Inc., H1 2015 81

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Bioheart, Inc., H1 2015 82

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Biotie Therapies Corp., H1 2015 83

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Boehringer Ingelheim GmbH, H1 2015 84

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by C4X Discovery Ltd, H1 2015 85

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Carolus Therapeutics, Inc., H1 2015 86

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 87

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Chiesi Farmaceutici SpA, H1 2015 88

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 89

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Corridor Pharmaceuticals Inc., H1 2015 90

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 91

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Cytokinetics, Inc., H1 2015 92

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 93

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Domainex Ltd., H1 2015 94

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Dong Wha Pharma Co., Ltd., H1 2015 95

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Errant Gene Therapeutics, LLC, H1 2015 96

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Five Prime Therapeutics, Inc., H1 2015 97

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 98

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Galapagos NV, H1 2015 99

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by GeneFrontier Corporation, H1 2015 100

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Gilead Sciences, Inc., H1 2015 101

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by GlaxoSmithKline plc, H1 2015 103

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by GlycoMar Limited, H1 2015 104

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Grifols, S.A., H1 2015 105

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 106

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by High Point Pharmaceuticals, LLC, H1 2015 107

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Hydra Biosciences, Inc., H1 2015 108

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by iCeutica, Inc., H1 2015 109

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Invion Limited, H1 2015 110

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 111

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Johnson & Johnson, H1 2015 112

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 113

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 114

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 115

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 116

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 117

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Medestea Research & Production S.p.A., H1 2015 118

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Microbion Corporation, H1 2015 119

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by MSM Protein Technologies, Inc., H1 2015 120

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by N30 Pharmaceuticals, H1 2015 121

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Nostrum Pharmaceuticals, LLC, H1 2015 122

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Novabiotics Ltd, H1 2015 123

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Novartis AG, H1 2015 124

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Ockham Biotech Limited, H1 2015 125

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by OPKO Health, Inc., H1 2015 126

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Orion Oyj, H1 2015 127

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 128

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by P2D Bioscience, H1 2015 129

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Panmira Pharmaceuticals, LLC., H1 2015 130

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Peptinnovate Limited, H1 2015 131

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Pfizer Inc., H1 2015 132

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by PharmaLundensis AB, H1 2015 133

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Pharmaxis Limited, H1 2015 134

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Promedior, Inc., H1 2015 135

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Prosonix Ltd, H1 2015 136

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Pulmagen Therapeutics LLP, H1 2015 137

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Pulmatrix, Inc., H1 2015 138

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Qu Biologics Inc., H1 2015 139

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Ranbaxy Laboratories Limited, H1 2015 140

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Re-Pharm Limited, H1 2015 141

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Recipharm AB, H1 2015 142

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Respiratorius AB, H1 2015 143

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Rhizen Pharmaceuticals SA, H1 2015 144

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Rottapharm SpA, H1 2015 145

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by SelectX Pharmaceuticals, Inc., H1 2015 146

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Seoul Pharma Co., Ltd., H1 2015 147

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by SkyePharma PLC, H1 2015 148

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Sparsha Pharma International Pvt. Ltd., H1 2015 149

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015 150

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Stelic Institute & Co., H1 2015 151

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Stempeutics Research Private Limited, H1 2015 152

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 153

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 154

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 155

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Syntrix Biosystems, Inc., H1 2015 156

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 157

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 158

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Theraclone Sciences, Inc., H1 2015 159

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Torrent Pharmaceuticals Limited, H1 2015 160

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Verona Pharma Plc, H1 2015 161

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Yuhan Corporation, H1 2015 162

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 163

Chronic Obstructive Pulmonary Disease (COPD)-Pipeline by Zambon Company S.p.A., H1 2015 164

Assessment by Monotherapy Products, H1 2015 165

Assessment by Combination Products, H1 2015 166

Number of Products by Stage and Target, H1 2015 168

Number of Products by Stage and Mechanism of Action, H1 2015 174

Number of Products by Stage and Route of Administration, H1 2015 179

Number of Products by Stage and Molecule Type, H1 2015 181

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics-Recent Pipeline Updates, H1 2015 445

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects, H1 2015 524

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..1), H1 2015 525

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..2), H1 2015 526

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..3), H1 2015 527

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..4), H1 2015 528

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..5), H1 2015 529

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..6), H1 2015 530

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..7), H1 2015 531

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..8), H1 2015 532

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..9), H1 2015 533

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..10), H1 2015 534

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..11), H1 2015 535

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..12), H1 2015 536

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..13), H1 2015 537

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..14), H1 2015 538

Chronic Obstructive Pulmonary Disease (COPD)-Dormant Projects (Contd..15), H1 2015 539

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products, H1 2015 540

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products (Contd..1), H1 2015 541

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products (Contd..2), H1 2015 542

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products (Contd..3), H1 2015 543

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products (Contd..4), H1 2015 544

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products (Contd..5), H1 2015 545

Chronic Obstructive Pulmonary Disease (COPD)-Discontinued Products (Contd..6), H1 2015 546

List of Figures

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2015 31

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD)-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 33

Number of Products under Investigation by Universities/Institutes, H1 2015 42

Comparative Analysis by Late Stage Development, H1 2015 44

Comparative Analysis by Clinical Stage Development, H1 2015 45

Comparative Analysis by Early Stage Products, H1 2015 46

Assessment by Monotherapy Products, H1 2015 165

Assessment by Combination Products, H1 2015 166

Number of Products by Top 10 Targets, H1 2015 167

Number of Products by Stage and Top 10 Targets, H1 2015 167

Number of Products by Top 10 Mechanism of Actions, H1 2015 173

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 173

Number of Products by Top 10 Routes of Administration, H1 2015 178

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 178

Number of Products by Top 10 Molecule Types, H1 2015 180

Number of Products by Stage and Top 10 Molecule Types, H1 2015 180

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ache Laboratorios Farmaceuticos S/A

Adamis Pharmaceuticals Corporation

Advinus Therapeutics Ltd.

Alba Therapeutics Corporation

Alchemia Limited

AlgiPharma AS

Amakem NV

Ampio Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

Aquinox Pharmaceuticals Inc.

Ario Pharma Ltd

Asmacure Ltee

Astellas Pharma Inc.

AstraZeneca PLC

Asubio Pharma Co., Ltd.

Axikin Pharmaceuticals, Inc.

Basilea Pharmaceutica AG

Beech Tree Labs, Inc.

Bioheart, Inc.

Biotie Therapies Corp.

Boehringer Ingelheim GmbH

C4X Discovery Ltd

Carolus Therapeutics, Inc.

Cellular Biomedicine Group, Inc.

Chiesi Farmaceutici SpA

Concert Pharmaceuticals, Inc.

Corridor Pharmaceuticals Inc.

Cubist Pharmaceuticals, Inc.

Cytokinetics, Inc.

Daiichi Sankyo Company, Limited

Domainex Ltd.

Dong Wha Pharma Co., Ltd.

Errant Gene Therapeutics, LLC

Five Prime Therapeutics, Inc.

Foresee Pharmaceuticals, LLC

Galapagos NV

GeneFrontier Corporation

Gilead Sciences, Inc.

GlaxoSmithKline plc

GlycoMar Limited

Grifols, S.A.

Hanmi Pharmaceuticals, Co. Ltd.

High Point Pharmaceuticals, LLC

Hydra Biosciences, Inc.

iCeutica, Inc.

Invion Limited

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Johnson & Johnson

KaloBios Pharmaceuticals, Inc.

Kissei Pharmaceutical Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

Laboratoires Pierre Fabre SA

LTT Bio-Pharma Co., Ltd.

Medestea Research & Production S.p.A.

Microbion Corporation

MSM Protein Technologies, Inc.

N30 Pharmaceuticals

Nostrum Pharmaceuticals, LLC

Novabiotics Ltd

Novartis AG

Ockham Biotech Limited

OPKO Health, Inc.

Orion Oyj

Otsuka Holdings Co., Ltd.

P2D Bioscience

Panmira Pharmaceuticals, LLC.

Peptinnovate Limited

Pfizer Inc.

PharmaLundensis AB

Pharmaxis Limited

Promedior, Inc.

Prosonix Ltd

Pulmagen Therapeutics LLP

Pulmatrix, Inc.

Qu Biologics Inc.

Ranbaxy Laboratories Limited

Re-Pharm Limited

Recipharm AB

Respiratorius AB

Rhizen Pharmaceuticals SA

Rottapharm SpA

SelectX Pharmaceuticals, Inc.

Seoul Pharma Co., Ltd.

SkyePharma PLC

Sparsha Pharma International Pvt. Ltd.

Spring Bank Pharmaceuticals, Inc.

Stelic Institute & Co.

Stempeutics Research Private Limited

sterna biologicals Gmbh & Co KG

Sucampo Pharmaceuticals, Inc.

Sunovion Pharmaceuticals Inc.

Syntrix Biosystems, Inc.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Limited

Theraclone Sciences, Inc.

Torrent Pharmaceuticals Limited

Verona Pharma Plc

Yuhan Corporation

Yungjin Pharm Ind. Co., Ltd.

Zambon Company S.p.A.

Chronic Obstructive Pulmonary Disease (COPD) Therapeutic Products under Development, Key Players in Chronic Obstructive Pulmonary Disease (COPD) Therapeutics, Chronic Obstructive Pulmonary Disease (COPD) Pipeline Overview, Chronic Obstructive Pulmonary Disease (COPD) Pipeline, Chronic Obstructive Pulmonary Disease (COPD) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com